Results 81 to 90 of about 9,061 (176)

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials

BACKGROUND: The EMBER-3 trial demonstrated significant progression-free survival (PFS) benefit for imlunestrant + abemaciclib versus imlunestrant alone in patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2 ...
Neven, P., Tolaney, S.M., Rugo, H.S., Jhaveri, K., Traore, S., Sapunar, F., Li, Y., Bidard, F.C., Laue, C.C. Von, Kalinsky, K., Litchfield, L.M., O'Shaughnessy, J.   +11 more
core   +1 more source

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

, 2019
At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable safety profile as initial treatment for hormone receptor-
Di Leo, A., Barriga, Susana, Johnston, Stephen Rd D S., Goetz, Matthew M.P., Toi, Masakazu, Awada, Ahmad, Frenzel, Martin, Forrester, Tammy, Iwata, Hiroji, Goetz, Matthew P., Di Leo, Angelo, Martin, Miguel, Hardebeck, Molly C., Hardebeck, Molly Catherine, Johnston, Stephen, Cox, Joanne, Im, Seock–Ah –A, Im, Seock-Ah   +17 more
core   +1 more source

Prophylaxis with abemaciclib delays tumorigenesis in dMMR mice by altering immune responses and reducing immunosuppressive extracellular vesicle secretion

Translational Oncology
Background: The CDK4/6 inhibitor abemaciclib is an FDA-approved agent and induces T-cell-mediated immunity. Previously, we confirmed the therapeutic potential of abemaciclib on mismatch repair-deficient (dMMR) tumors in mice.
Annabell Wolff, Paula Krone, Johanna Maennicke, Julia Henne, Sonja Oehmcke-Hecht, Caterina Redwanz, Wendy Bergmann-Ewert, Christian Junghanss, Larissa Henze, Claudia Maletzki   +9 more
doaj   +1 more source

Abemaciclib early access - an Italian experience [PDF]

Italian legislation allows pharmaceutical companies to market drugs authorized through the centralized procedure before price negotiation with the Italian Medicines Agency (AIFA), placing them in the C(nn) category, which indicates non-reimbursed and non-
Eleonora Cannella, Patrizia Nardulli, Concetta Calabrò   +2 more
core   +1 more source

Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib

BACKGROUND: Two years of adjuvant abemaciclib with endocrine therapy (ET) is standard for high-risk estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, node-positive early-stage breast cancer.
Abravanel, D.L., Mittendorf, E.A., Abravanel, D L, Curigliano, G, Mittendorf, E A, Lin, N U, Tarantino, P., Kurnia, P.T., Corti, C, Kurnia, P T, Tolaney, S M, Parker, T., Gómez Tejeda Zañudo, J, Parker, T, Tolaney, S.M., Tarantino, P, King, T.A., Gómez Tejeda Zañudo, J., Lin, N.U., Hughes, M.E., Martin, A.R., Hughes, M E, Corti, C., Martin, A R, Curigliano, G., King, T A   +25 more
core   +1 more source

Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review [PDF]

Abemaciclib (ABE) in combination with endocrine therapy represents the mainstay treatment for either endocrine-resistant metastatic or high-risk early-stage HR+/HER2- breast cancer patients.
Valerio M. R., Gebbia V., Sano M. V., Vigneri P., Danesi R., Martorana F., Fogli S.   +6 more
core   +1 more source

Recommended phase 2 dose for abemaciclib in combination with irinotecan and temozolomide in pediatric and young adult patients with relapsed/refractory solid tumors: Results from JPCS study (Part A)

EJC Paediatric Oncology
Background: Abemaciclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor approved for breast cancer. The CDK4/6 pathway is essential for cell cycle progression. Pediatric cancers often harbor aberrations in this pathway, potentially rendering sensitivity
Antonio Juan Ribelles, Lucas Moreno, Chitose Ogawa, Anne Thorwarth, Antonio Ruggiero, Celine Pitou, Yanhong Zhou, Molly C. Hardebeck, Holly Knoderer, Alvaro Lassaletta   +9 more
doaj   +1 more source

Abstract P1-10-14: Abemaciclib tablet formulation is bioequivalent to capsules

, 2018
Introduction: Abemaciclib is being developed for the treatment of cancer, including advanced and metastatic breast cancer. Tablet formulations, which are smaller than the capsules used in the pivotal MONARCH 1, 2 and 3 breast cancer studies, have ...
PK Turner, A Aburub, J Royalty, WT Ng, JC Chappell, W Zhang, P Kulanthaivel   +6 more
core   +1 more source

Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study

BMC Cancer
Background Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy are now standard of care in the first- or second-line settings for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) patients with advanced /
Judy King, Walid Fakhouri, Rosalind Jarvis, Waleed Badreldin, Gavin Harper, Carlo Palmieri, Mark Nathan   +6 more
doaj   +1 more source

Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer

Nature Communications
The efficacy of cancer immunotherapy relies on a sufficient amount of functional immune cells. Triple-negative breast cancer lacks enough immune cell infiltration, and adjuvant therapy is necessary to prime anti-tumor immunity.
Binyu Zhu, Ying Cai, Lingli Zhou, Lei Zhao, Jiameng Chen, Xiaoting Shan, Xujie Sun, Qian You, Xiang Gong, Wen Zhang, Helen He Zhu, Pengcheng Zhang, Yaping Li   +12 more
doaj   +1 more source